REDMOND, WA, MARCH 9, 2022 – Pattern Computer®, Inc. (PCI) is pleased to announce that the application of its Pattern Discovery Engine™ to Namida Lab’s data resulted in significant improvement to the predictive accuracy of Namida Lab’s diagnostic test for breast cancer and allowed for acceleration in company’s development timeline for an inexpensive, and accurate diagnostic test for breast cancer.

Omid Moghadam, CEO of Namida Lab, explained:

“The challenge in developing an inexpensive biomarker-based cancer screening test that can be widely distributed is finding the relevant and small disease signal in the mountain of biological noise within the body.

The collaboration between Pattern Computer’s data scientists and Namida Lab’s research and clinical teams uncovered a number of previously undetectable biomarker combinations that both enhanced the performance of Namida’s current biomarker-based breast cancer screening test and enabled delivery of a diagnostic test in the near future. We are looking forward to put data generated by our R&D programs in other types of cancer thru PCI’s Discovery Engine.”

Mark Anderson, CEO of Pattern Computer, added:

“We are delighted that our Discovery Engine was able to assist Namida Lab in getting world-class results in their tear-based breast cancer screening test. We look forward to working with Namida Lab in the future on additional oncology screening tests, and to having a long and fulfilling partnership. There is nothing our team likes better than to help saving lives through making Pattern Discoveries.

Having also just gone into production with our best-in-class ProSpectral COVID spit-based screening and diagnostic test system, it would appear that “Powered By Pattern Computer” is on its way to becoming a prime driver in medical screening on many fronts.”

About Pattern Computer

Pattern Computer, Inc. uses its proprietary Pattern Discovery Engine to solve the most important and intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by others.

While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making Pattern Discoveries for partners in other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, resource extraction and finance.

CONTACT: Brad Holtz – 301.529.9944 – bh@patterncomputer.com

The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.

Copyright © 2022 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, ProSpectral and Powered By Pattern Computer are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.